Drugs / SPC3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002363 | — | HIV infectious disease | Columbia Research Laboratories | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPC3 | “The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients” NCT00002363 ↗ |
| Known as | synthetic peptide construction 3 | “synthetic peptide construction 3 ( SPC3 )” NCT00002363 ↗ |
| Route | Intravenous | “Administered Daily Intravenously” NCT00002363 ↗ |